Decision Resources Group Release: A Focus on Specialty Pharmacy at Las Vegas Pharmaceutical Conference
8/15/2012 9:55:47 AM
More...
|
Decision Resources Group Release: Keynote Speakers Announced for Sixth Annual Pinsonault Managed Markets Summit
7/26/2012 10:06:53 AM
More...
|
Decision Resources Group Release: Competition for Early-Line Biologic Use Among Psoriasis Patients Intensifies as Humira Continues to Gain Ground on Enbrel
10/5/2011 8:52:45 AM
More...
|
Decision Resources Group Release: Over the Next Decade, the Malignant Melanoma Drug Market Will Increase More Than Seven-Fold to $1.5 Billion in 2020
10/4/2011 8:48:48 AM
More...
|
Decision Resources Group Release: Biosimilar Versions of TNF-alpha Inhibitors and Pegylated IFN-alpha Agents Will Save Healthcare Systems $5.3 Billion in 2020
10/3/2011 9:56:31 AM
More...
|
Decision Resources Group Acquires PharmaStrat
7/25/2011 10:46:53 AM
More...
|
Decision Resources, Inc. Finds Despite FDA Label Revisions Regarding LABA-Containing Drugs, Patient Share of LABA/ICS Combination Drugs Exceed Patient Share of Single-Agent ICS Drugs in Recently Treated Asthma Patients
7/20/2011 6:55:19 AM
More...
|
Decision Resources, Inc. Release: The Majority of Surveyed U.S. Oncologists Identified FOLFIRINOX as the Most Efficacious Treatment for Advanced Pancreatic Cancer, When Compared to Other Currently Available Therapies
3/3/2011 10:26:02 AM
More...
|
Decision Resources, Inc. Release: Virtually the Same Percentage of Surveyed Rheumatologists Selected Enbrel and Humira as the Most Efficacious Agent for the Treatment of Rheumatoid Arthritis
3/1/2011 10:37:11 AM
More...
|
Decision Resources, Inc. Release: For the Treatment of Acute Heart Failure, the Highest Proportion of Surveyed Cardiologists Identify Furosemide as the Most Efficacious Agent, When Compared to Other Available Therapies
2/28/2011 9:43:51 AM
More...
|
|